AI can be a highly effective tool for plans aiming to reduce fraud, waste and abuse, but only if it is combined with investigative intelligence. The post AI: A Good Tool to Combat Bad Actors in Healthcare appeared first on MedCity News.
AI-assisted software development can help teams achieve faster delivery, lower costs, and higher-quality results – all key to meeting patients’ and providers’ digital health expectations. The post The Future of Healthcare Apps Depends on AI-Assisted Development appeared first on MedCity News.
CMS recently issued a statement saying that it’s continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see. The post Could the Trump Administration Change the Medicare Drug Price Negotiation Program? appeared…
Sionna Therapeutics found strong investor interest in its cystic fibrosis drugs, which could rival blockbuster Vertex Pharmaceuticals product Trikafta. The biotech has three internally developed programs that hit a target unaddressed by any currently available CF therapies. The post Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline appeared first on…
At a moment when medication therapy for sickle cell disease (SCD) leaves too many behind and widespread access to curative gene therapies still lies in the distant future, automated red blood cell exchange is experiencing renewed interest. To improve patients’ lives, a broad commitment is needed to expand access to transfusion therapies. The post Beyond…
Kennedy emphasized that these inefficiencies aren’t just administrative headaches, they’re costing lives. Nowhere is this more evident than in organ-transplant logistics: the way organs get assigned – and move – from donors to patient recipients. The post RFK’s Hearing: Inefficiencies in Government-Controlled Systems appeared first on MedCity News.
Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group. The post Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma…
Fay’s $50 million Series B round was led by Goldman Sachs. In total, the company has raised $75 million. The post Fay Raises $50M to Expand Access to Nutrition Counseling Services appeared first on MedCity News.
It’s time to replace this system with one that works for patients and invites disruption. We need to put control back in the hands of patients, allowing them to own their health records, make independent decisions, and switch to fair and transparent alternatives. The post The End of Corporate-Controlled Care? AI and Patient Access Fuel…
The evolving landscape of healthcare demands that health plans continuously refine their engagement strategies, making this decision more critical than ever. Plan leaders must consider key factors, including cost, speed, scalability, and effectiveness, to guide them toward the most impactful approach. The post Navigating the Build vs. Buy Debate for Member Engagement Solutions appeared first…